Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;31(5):473-82.
doi: 10.1016/j.cct.2010.05.010. Epub 2010 Jun 2.

A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials

Affiliations

A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials

Zhengjia Chen et al. Contemp Clin Trials. 2010 Sep.

Abstract

In almost all current Phase I designs, toxicity response is treated coarsely as a binary indicator of dose limiting toxicity (DLT) and a lot of useful toxicity information is discarded. We are the first to establish a novel toxicity scoring system to treat toxicity response as a quasi-continuous variable and utilize all toxicities in Phase I trial. The generally accepted and objective parts, such as a logistic function, grade and type of toxicity, and whether the toxicity is DLT, are used so that the toxicity scoring system is relatively objective. Our toxicity scoring system has been successfully applied to an isotonic design (ID) to develop an extended isotonic design (EID). Simulation study and application of EID to the data of a real Phase I trial demonstrate that EID can always estimate a more accurate maximum tolerated dose (MTD) according to the exact toxicity profile under any toxicity profiles without additional cost or length of the trial. These cannot be accomplished in designs using a binary indicator of DLT, such as Standard 3+3 design, ID, and continual reassessment method (CRM). Moreover, our EID is relatively objective, model free, and simple to use. Our toxicity scoring system can also be applied to other designs, such as CRM and escalation with overdose control (EWOC), to improve their efficiency and accuracy in MTD estimation by utilizing all toxicities. Our novel toxicity scoring system and EID may help to begin a new era in which toxicity response is treated as a continuous variable.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Decimal part of ETS contributed by other toxicities with maximum adjusted grade besides the “worst” toxicity using different values of β while α=−2 and all wi =1.

References

    1. Leung DH, Wang YG. Isotonic designs for phase I trials. Control Clin Trials. 2001;22:126–38. - PubMed
    1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical studies in cancer. Biometrics. 1990;46:33–48. - PubMed
    1. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17:1103–20. - PubMed
    1. Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Stat Med. 2002;21:2757–70. - PubMed
    1. Potter D. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs. J Biopharm Stat. 2006;16:579–604. - PubMed

Publication types

MeSH terms

LinkOut - more resources